Table 2.
Baseline characteristics of patients at index or during 12 months before index prescription
| Methotrexate (MTX) | Biologics/tofacitinib (B/T) | |||||
|---|---|---|---|---|---|---|
| Noninitiators (n = 281) |
Initiators (n = 482) |
Total (n = 763) |
Noninitiators (n = 176) |
Initiators (n = 258) |
Total (n = 434) |
|
| Age at index prescription, mean (SD) | 67.6 (12.7) | 59.5 (13.5) | 62.5 (13.8) | 63.0 (13.7) | 54.0 (13.4) | 57.7 (14.2) |
| Female (%) | 73.3 | 71.6 | 72.2 | 74.4 | 77.1 | 76.4 |
| Race (%) | ||||||
| White | 87.5 | 78.4 | 81.8 | 83.0 | 80.2 | 81.3 |
| African American | 5.7 | 8.1 | 7.2 | 5.1 | 7.4 | 6.5 |
| Asian | 2.1 | 2.1 | 2.1 | 0.6 | 1.2 | 0.9 |
| Other/unknown | 4.6 | 11.4 | 8.9 | 11.4 | 11.2 | 11.3 |
| Geographic division (%)a | ||||||
| East North Central | 14.2 | 23.2 | 19.9 | |||
| East South Central | 1.8 | 0.8 | 1.2 | |||
| Middle Atlantic | 5.7 | 10.0 | 8.4 | |||
| Mountain | 2.1 | 2.9 | 2.6 | |||
| New England | 16.7 | 3.1 | 8.1 | |||
| Other/unknown | 1.8 | 2.5 | 2.2 | |||
| Pacific | 8.2 | 8.9 | 8.7 | |||
| South Atlantic/West South Central | 24.2 | 36.9 | 32.2 | |||
| West North Central | 25.3 | 11.6 | 16.6 | |||
| Commercial insurance (vs Medicare) at index (%)a,b | 29.9 | 58.5 | 47.7 | 34.1 | 79.5 | 61.5 |
| Body mass index during 12 months before index (from EHRs) (%)a | ||||||
| Underweight (< 18.5) | 1.4 | 2.1 | 1.8 | |||
| Healthy weight (18.5–24.9) | 16.4 | 21.4 | 19.5 | |||
| Overweight (25.0–29.9) | 20.6 | 23.9 | 22.7 | |||
| Obesity I (30.0–34.9) | 11.7 | 18.5 | 16.0 | |||
| Obesity II (35.0–39.9) | 6.4 | 8.5 | 7.7 | |||
| Obesity III (40.0+) | 5.3 | 7.9 | 6.9 | |||
| Missing | 38.1 | 17.8 | 25.3 | |||
| Active ingredient counts during 12 months before index (from claims)a, mean (SD) | 3.4 (6.4) | 10.5 (6.8) | 7.9 (7.5) | |||
| Number of days between RA diagnosis (from claims) and first prescription (from EHRs)a, median; mean (SD) | 371 | 39 | 90 | |||
| 602 | 279 | 398 | ||||
| (698) | (502) | (602) | ||||
| Diagnosis-based comorbidity indicators (EDCs) during 12 months before index (based on claims) (%) | ||||||
| ADM05: administrative concerns and nonspecific laboratory abnormalitiesa | 70.5 | 60.0 | 63.8 | |||
| GUR11: incontinencea | 6.0 | 1.2 | 3.0 | |||
| Pharmacy-based comorbidity indicators (RxMGs) during 12 months before index (based on claims) (%) | ||||||
| MUSx020: musculoskeletal/inflammatory conditionsb | 71.6 | 91.5 | 83.4 | |||
| ALLx030: allergy/immunology/chronic inflammatorya,b | 14.2 | 66.6 | 47.3 | 47.2 | 76.0 | 64.3 |
| CARx030: cardiovascular/high blood pressurea | 13.5 | 45.4 | 33.7 | |||
| GSIx020: general signs and symptoms/paina | 17.8 | 59.1 | 43.9 | |||
| GSIx030: general signs and symptoms/pain and inflammationa | 12.5 | 56.4 | 40.2 | |||
| INFx020: infections/acute minora | 18.1 | 61.2 | 45.3 | |||
| ENDx040: endocrine/diabetes without insulina | 0.7 | 11.0 | 7.2 | |||
SD standard deviation, EHR electronic health record, RA rheumatoid arthritis, EDC Expanded Diagnosis Cluster, RxMG Rx-defined Morbidity Group
aImportant predictors selected by LASSO logistic regression for predicting MTX primary nonadherence
bImportant predictors selected for predicting B/T primary nonadherence; age, sex, and race were added to the predictive models regardless